• Liver cirrhosis leads to poorer survival in patients with end-stage renal disease

• ±è¾ÖÁø(Kim Ae-Jin) ÀÓÇýÁø(Lim Hye-Jin) ³ëÇÑ(Ro Han) Á¤Áö¿ë(Jung Ji-Yong) ÀÌÇöÈñ(Lee Hyun-Hee) Á¤¿ì°æ(Chung Woo-Kyung) ÀåÁ¦Çö(Chang Jae-Hyun)

• The Korean Journal of Internal Medicine  2016³â 31±Ç 4È£ 730~738

• Impact of dialysis modality on technique survival in end-stage renal disease patients

• ÀÌÁ¾ÇÐ(Lee Jong-Hak) ¹Ú¼øÈñ(Park Sun-Hee) ÀÓÁ¤ÈÆ(Lim Jeong-Hoon) ¹Ú¿µÀç(Park Young-Jae) ±è»ó¿î(Kim Sang-Un) ÀÌ°æÈñ(Lee Kyung-Hee) ±è°æÈÆ(Kim Kyung-Hoon) ¹Ú½ÂÂù(Park Seung-Chan) Á¤Èñ¿¬(Jung Hee-Yeon) (Kwon Owen) ÃÖÁö¿µ(Choi Ji-Young) Á¶ÀåÈñ(Cho Jang-Hee) ±èÂù´ö(Kim Chan-Duck) ±è¿ë¸²(Kim Yong-Lim)

• The Korean Journal of Internal Medicine  2016³â 31±Ç 1È£ 106~115

• Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼® ȯÀÚ¿¡¼­ ¹ß»ýÇÑ ¸¸¼º °áÀý¼º Åëdz Ä¡·á 1¿¹

• Febuxostat for the Treatment of Chronic Tophaceous Gout in a Patient on Continuous Ambulatory Peritoneal Dialysis

• À±Á¤Èñ(Yun Jeong-Hee) ±èÈñ¿¬(Kim Hee-Yeoun) ±èµ¿ÇÑ(Kim Dong-Han) ¿ÀÁؼ®(Oh Joon-Seok) ±è¼º¹Î(Kim Sung-Min) ½Å¿ëÈÆ(Shin Yong-Hun) ±èÁß°æ(Kim Joong-Kyung)

• ´ëÇѳ»°úÇÐȸÁö  2015³â 89±Ç 2È£ 229~232

• Lessons from 30 years¡¯ data of Korean end-stage renal disease registry, 1985?2015

• :Jin Dong-Chan :Kim Yong-Kyun/:Yun Sung-Ro/:Lee Seoung-Woo/:Han Sang-Woong/:Kim Won/:Park Jong-ha

• ´ëÇѽÅÀåÇÐȸÁö  2015³â 34±Ç 3È£ 132~139

• Excess mortality among patients on dialysis: Comparison with the general population in Korea

• ÃÖÇü¿¬(Choi Hyung-Yun) ±è¸íÈñ(Kim Myoung-Hee) ±èÇö¿í(Kim Hyun-Wook) ÀÌÁ¤Ç¥(Lee Jung-Pyo) ÀÌÁ¤È¯(Lee Jeong-Hwan) ¹ÚÁ¤Å¹(Park Jung-Tak) ±è°æÈ£(Kim Kyoung-Hoon) ¾ÈÇü½Ä(Ahn Hyeong-Sik) ÇÑÈÄÀç(Hann Hoo-Jae) ·ùµ¿¿­(Ryu Dong-Ryeol)

• ´ëÇѽÅÀåÇÐȸÁö  2014³â 33±Ç 2È£ 89~94

• º¹¸·Åõ¼® ȯÀÚ¿¡¼­ Methoxy Polyethylene Glycol-epoetin Beta ÇÇÇÏ Åõ¿©°¡ ºóÇ÷°ú ¿µ¾çÁöÇ¥¿¡ ¹ÌÄ¡´Â È¿°ú

• Effect of Subcutaneous Methoxy Polyethylene Glycol-epoetin Beta on Anemia and Nutritional Indices in Peritoneal Dialysis Patients

• ±è°æ¼÷(Kim Kyung-Sook) ÀÌÁؼ·(Lee Jun-Seop) ±èÇý¿µ(Kim Hye-Young) ÀÌ¸í±¸(Lee Myung-Koo)

• Çѱ¹ÀÓ»ó¾àÇÐȸÁö  2012³â 22±Ç 3È£ 202~210

• Comparison of Vascular Calcification Scores on Plain Radiographs to Predict Coronary Artery Disease According to Dialysis Modality

• ±èÁظð(Kim Joon-Mo) ±èÁ¤¹Î(Kim Jung-Min) À̼ö¹Ì(Lee Su-Mi) À¯½ÂÈñ(Ryu Seung-Hee) ±è±âÇö(Kim Ki-Hyun) ±è¼ºÀº(Kim Seong-Eun) ¼Õ¿µ±â(Son Young-Ki) ÇÑÁø¿µ(Ham Jin-Yeong) Çϵ¿È£(Ha Dong-Ho) ¾È¿ø¼®(An Won-Suk)

• ´ëÇѽÅÀåÇÐȸÁö  2011³â 30±Ç 3È£ 292~301

• Comparison of Clinical Outcomes by Different Renal Replacement Therapy in Patients with End-Stage Renal Disease Secondary to Lupus Nephritis

• °­¼®ÈÖ(Kang Seok-hui) Á¤º´ÇÏ(Chung Byung-Ha) ÃÖ¼±·É(Choi Sun-Ryoung) ÀÌÀÚ¿µ(Lee Ja-Young) ¹ÚÈƼ®(Park Hoon-Suk) ¼±ÀοÀ(Sun In-O) ÃÖ¹ü¼ø(Choi Bum-Soon) ¹ÚöÈÖ(Park Cheol-Whee) ±è¿µ¼ö(Kim Yong-Soo) ¾çö¿ì(Yang Chul-Woo)

• The Korean Journal of Internal Medicine  2011³â 26±Ç 1È£ 60~67

• ¸»±â ½ÅºÎÀüÁõÀ¸·Î Åõ¼®À» ¹Þ´Â ȯÀÚ¿¡¼­ ¹ß»ýÇÑ ½ÅÁ¾±«ÀÇ ÀÓ»óÀû Ư¡

• Renal masses in end-stage renal disease patients on dialysis

• À̹ÌÁ¤(Lee Mi-Jung) ½Åµ¿È£(Shin Dong-Ho) ±èÇö¹Î(Kim Hyun-Min) ¹ÚÇö¼º(Park Hyun-Sung) ¹ÚÁ¤Å¹(Park Jung-Tak) ÀåÅÂÀÍ(Chang Tae-Ik) À¯ÅÂÇö(Yoo Tae-Hyun) °­½Å¿í(Kang Shin-Wook) ÃÖ±ÔÇå(Choi Kyu-Hun)

• ´ëÇѳ»°úÇÐȸÁö  2010³â 79±Ç 3È£ 263~270

• Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼®µµ°ü »ðÀÔ¼ú½Ã À¯Âø¹æÁöÁ¦ÀÇ È¿°ú

• The Effect of an Anti-adhesion Agent in Continuous Ambulatory Peritoneal Dialysis (CAPD) Catheter Insertion Operation

• ±è±âȯ(Kim Ki-Hwan) ³ë¿µÈÆ(Roh Young-Hoon) ±è¿µÈÆ(Kim Young-Hoon) Á¤°©Áß(Jung Ghap-Joong) ¾È¿ø¼®(An Won-Suk) ±è¼ºÀº(Kim Sung-Eun) ±è±âÇö(Kim Ki-Hyun)

• ´ëÇÑ¿Ü°úÇÐȸÁö  2010³â 78±Ç 2È£ 71~76

• ºñ´ç´¢º´¼º ¸»±â½ÅºÎÀü ȯÀÚ¿¡¼­ ½ÉÇ÷°üÁúȯ ¹ß»ýÀÇ ¿¹Ãø ÀÎÀڷμ­ ¾ÆµðÆ÷³ØƾÀÇ À¯¿ë¼º

• Serum Adiponectin as a Predictor for Cardiovascular Outcomes in Non-Diabetic End-Stage Renal Disease Patients

• ¾ÈÇý¸²(An Hye-Rim) ¹®¼ºÁø(Moon Sung-Jin) ¹ÚÇüõ(Park Hyeong-Cheon) ÀÌ¿ë±Ô(Lee Yong-Kyu) ±èÁ°æ(Kim Jwa-Kyung) ±è¹ü¼®(Kim Beom-Seok) ±èÇüÁ¾(Kim Hyung-Jong) ÇÑ´ë¼®(Han Dae-Suk) Çϼº±Ô(Ha Sung-Kyu)

• ´ëÇѽÅÀåÇÐȸÁö  2010³â 29±Ç 4È£ 465~473

• Ezetimibe°¡ ¸»±â ½ÅºÎÀü ȯÀÚÀÇ Ç÷Áß ÁöÁú ¹× Ç÷Àü ÁöÇ¥¿¡ ¹ÌÄ¡´Â ¿µÇâ

• Effects of ezetimibe on lipid profiles and hemostatic markers in end-stage renal disease

• ¹Ú°æ¼±(Park Kyung-Sun) ¿©¿µ¼±(Yeo Young-Sun) À¯¹ÌÇö(Yu Mi-Hyun) ÃÖÁؼ®(Choi Jun-Seok) ÀåÁö¿õ(Jang Ji-Woong) ºÎ¼±Áø(Boo Sun-Jin) À¯µ¿ÁØ(Yoo Dong-Jun) ±è¼ø¹è(Kim Soon-Bae)

• ´ëÇѳ»°úÇÐȸÁö  2009³â 77±Ç 4È£ 461~471

• ¸»±â ¸¸¼º ÄáÆϺ´ ȯÀÚ¿¡¼­ »õ·Î¿î Åõ¼®Ä¡·á

• New dialysis treatment options for patients with end-stage chronic kidney disease

• À±ÇýÀº(Yoon Hye-Eun) ±è¿ë¼ö(Kim Yong-Soo)

• ´ëÇѳ»°úÇÐȸÁö  2009³â 76±Ç 5È£ 528~537

• The Relation of Arterial Stiffness with Vascular Calcification and BMD in Chronic Kidney Disease

• ½Å¿µ½Å(Shin Young-Shin) ½Å¹ÌÁ¤(Shin Mi-Jung) ¼Ûȣö(Song Ho-Cheol) ±è´ë¹ü(Kim Dae-Bum) ±è¿µ¼ö(Kim Young-Soo) ±èº´¼ö(Kim Byung-Soo) ±è¿µ¿Á(Kim Young-Ok) ±è¿ë¼ö(Kim Yong-Soo)

• ´ëÇѽÅÀåÇÐȸÁö  2009³â 28±Ç 5È£ 433~443

• The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival

• ±è¼º±¸(Kim Seoung-Gu) ±è³²È£(Kim Nam-Ho)

• The Korean Journal of Internal Medicine  2009³â 24±Ç 1È£ 55~62

• ÀüÈ­ÃßÈÄ°ü¸® ÇÁ·Î±×·¥ÀÌ º¹¸·Åõ¼®È¯ÀÚÀÇ Ä¡·áÁö¼ÓÀÌÇà, Åõ¼®ÀûÀýµµ¿Í °¨¿°¹ß»ýµµ¿¡ ¹ÌÄ¡´Â È¿°ú

• Effects of a Telephone Follow-up Program on Patient Compliance, Urea Kinetic Modeling and Incidence of Infection in Patients with Continuous Ambulatory Peritoneal Dialysis (CAPD)

• Àü½ÃÀÚ(Chon Si-Ja) ½Å¼®±Õ(Shin Sug-Kyun) ³ë¿µ¼÷(Roh Young-Sook) À̼÷Á¤(Lee Suk-Jeong) ¹Ú¾ÖÈñ(Park Ai-Hee) ¹Ú¾ç¼÷(Park Yang-Sook) ¹Ú¿µ¹Ì(Park Young-Mi)

• °¡Á¤°£È£ÇÐȸÁö  2009³â 16±Ç 2È£ 98~107

• ¸»±â ½ÅÁúȯ ȯÀڵ鿡¼­ ¹ß»ýÇÑ ¸»ÃʽŰ溴Áõ

• Peripheral Neuropathy in Patients with End-Stage Renal Disease

• °­¼®(Kang Seok) ±ÇÈñ±Ô(Kwon Hee-Kyu) Æí¼º¹ü(Pyun Sung-Bom) ±è±ÔÅÂ(Kim Kyu-Tae) ÀÌÀ¯³ª(Yi Yoo-Na) À±Çü¼®(Yun Hyung-Seok) ºÎâ¼ö(Boo Chang-Su) Á¶¿ø¿ë(Cho Won-Yong)

• ´ëÇѱÙÀüµµÀü±âÁø´ÜÀÇÇÐȸÁö  2009³â 11±Ç 2È£ 55~60

• º¹¸·Åõ¼®È¯ÀÚ¿¡¼­ º¹°­ ³» Ä®½ÃÆ®¸®¿Ã Ãæ°Ý¿ä¹ýÀÇ ºÎ°©»ó¼± È£¸£¸ó ¾ïÁ¦È¿°ú

• The Effect of Intraperitoneal Calcitriol Pulse Therapy in CAPD Patients with Secondary Hyperparathyroidism

• ¼Ûȣö(Song Ho-Cheol) À¯¼±È«(Yoo Sun-Hong) Á¤ÇöÈ­(Chung Hyun-Wha) ±è¿ë±Õ(Kim Yong-Kyun) ½Å¼®ÁØ(Shin Seok-Joon) ±èº´¼ö(Kim Byung-Soo) ±è¿µ¿Á(Kim Young-Ok) ±è¿ë¼ö(Kim Yong-Soo) ÃÖÀÇÁø(Choi Euy-Jin)

• ´ëÇѽÅÀåÇÐȸÁö  2008³â 27±Ç 6È£ 707~711

• º¹¸·Åõ¼® ȯÀÚ¿Í Ç÷¾×Åõ¼® ȯÀÚ¿¡¼­ ³»Àå ºñ¸¸ÀÇ À¯º´·ü ºñ±³

• omparison of Prevalence of Visceral Obesity between Hemodialysis and Peritoneal Dialysis Patients

• ±¸¿µ¹Ì(Ku Young-Mi) Á¤¼ö±³(Chung Soo-Kyo) ±è¿ë¼ö(Kim Yong-Soo) ¿°±Ù»ó(Yum Keun-Sang) ±è¿µ¼ö(Kim Young-Soo) À±¼±¾Ö(Yoon Sun-Ae) ¼Ûȣö(Song Ho-Cheol) ±è¿µ¿Á(Kim Young-Ok) ¹Î°æÈñ(Min Kyoung-Hee) Á¤¼ø¼±(Jung Soon-Sun)

• ´ëÇѽÅÀåÇÐȸÁö  2008³â 27±Ç 4È£ 458~464

• ¿øÀú : »ýüÀü±â ÀÓÇÇ´ø½º ºÐ¼®±â¸¦ ÀÌ¿ëÇÑ ½ÅÀÌ½Ä ÈÄ Ã¼¼öºÐ ºÐÆ÷ÀÇ º¯È­

• Change of Body Composition Analyzed by Bioelectrical Impedance Analysis (BIA) in Renal Transplant Recipients

• ÇãÀΰæ(Hur In-Kyong) ÀÌÀº¿µ(Lee Eun-Young) Á¶ÁöÇü(Cho Ji-Hyung) ÃÖÁö¿µ(Choi Ji-Young) ¹Ú¼±Èñ(Park Sun-Hee) ±èÂù´ö(Kim Chan-Duck) ±è¿ë¸²(Kim Yong-Lim)

• ´ëÇѽÅÀåÇÐȸÁö  2008³â 27±Ç 2È£ 211~219

• ¸¸¼º º¹¸·Åõ¼® ȯÀÚ¿¡¼­ ¼ºÀåÈ£¸£¸ó Ä¡·áÀÇ È¿°ú¿Í ¼ºÀå¿¡ ¿µÇâÀ» ÁÖ´Â ¿äÀο¡ ´ëÇÑ ¿¬±¸

• The Effect of Growth Hormone and the Factors Influencing Growth in Pediatric Chronic Peritoneal Dialysis Patients

• ±è¼öÁø(Kim Su-Jin) ¹é°æÈÆ(Paik Kyung-Hoon) Áøµ¿±Ô(Jin Dong-Kyu) ¼Õ¿µ¹è(Sohn Young-Bae) ¹Ú¼º¿ø(Park Sung-Won)

• ´ëÇѼҾƽÅÀåÇÐȸÁö  2008³â 12±Ç 1È£ 38~46

• ¸»±â½ÅÁúȯÀÚ¿¡¼­ È£¸ð½Ã½ºÅ×Àγ󵵿¡ µû¸¥ ¿±»êÀÇ Ä¡·áÈ¿°ú ¹× Pulse wave velocity (PWV) ÀÇ º¯È­

• Changes of pulse wave velocity findings and the effects of folic acid treatment on homocysteine levels in End Stage Renal Disease

• °íÀç±â(Koh Jae-Ki) ±è¼öÇö(Kim Su-Hyun) ½Å¼®È£(Shin Suk-Ho) Àü°ü¼±(Chun Kwan-Sun) ÃÖÁØÇõ(Choi Jun-Hyouck) ÀÓÁöȯ(Lim Ji-Hwan) À±¼öÁø(Yoon Su-Jin)

• ´ëÇѳ»°úÇÐȸÁö  2007³â 72±Ç 6È£ 607~615

• °£°æº¯ÁõÀÌ µ¿¹ÝµÈ ¸»±â½ÅºÎÀüÁõȯÀÚ¿¡¼­ÀÇ ½Å´ëü ¿ä¹ý

• Comparison between Hemodialysis and Peritoneal Dialysis in Patients with End-stage Renal Disease and Liver Cirrhosis

• ±è¹Î¼ö(Kim Min-Su) ¾çÀç¿ø(Yang Jae-Won) ÇѽÂÅÂ(Han Seung-Tae) ±èÀç¼®(Kim Jae-Seok) ±èºñ·Î(Kim Bi-Ro) ÇѺ´±Ù(Han Byoung-Geun) Ãֽ¿Á(Choi Seung-Ok)

• ´ëÇѽÅÀåÇÐȸÁö  2007³â 26±Ç 6È£ 705~715

• ¸»±â½ÅºÎÀü ȯÀÚ¿¡¼­ Åõ¼®Ä¡·áÀÇ ½ÃÀÛÀÌ ¿°Áõ»óÅ ¹× ¸é¿ª¹ÝÀÀ¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ °üÇÑ ¿¬±¸

• Effect of Initiating Dialysis on Inflammatory State and Immune Response in Patients with End-stage Renal Disease

• ÀÌÀç¿ø(Lee Jae-Won) ±èÇý¿ø(Kim Hye-Won) ¹ÚÀº¹ü(Park Eun-Bum) ºÎâ¼ö(Boo Chang-Su) °í°­Áö(Ko Gang-Jee) Á¶»ó°æ(Jo Sang-Kyung) Á¶¿ø¿ë(Cho Won-Yong) ±èÇü±Ô(Kim Hyung-Kyu)

• ´ëÇѽÅÀåÇÐȸÁö  2007³â 26±Ç 5È£ 559~566

• Åõ¼®À» ½ÃÇà ¹Þ´Â È¯ÀÚ¿¡¼­ ¹ß»ýÇÑ Àڹ߼º µÎ°³³»ÃâÇ÷¿¡ ´ëÇÑ ÀÓ»óÀû °íÂû

• Spontaneous Intracerebral Hemorrhage in the Patients Undergoing Dialysis Therapy

• ±¸¼±È£(Koo Sun-Ho) ¹ÚÇü±â(Park Hyung-Ki) ±è¹üÅÂ(Kim Bum-Tae) ÀåÀçÄ¥(Jang Jae-Chil) ÃÖ¼ø°ü(Choi Soon-Kwan)

• Journal of Cerebrovascular and Endovascular Neurosurgery  2007³â 9±Ç 2È£ 111~116

• Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼® ȯÀÚ¿¡¼­ °í¿ë·®(10,000 IU) Epoetin alfaÀÇ È¿°ú¿¡ ´ëÇÑ ±³Â÷ ¿¬±¸

• Efficacy and safety of high dose epoetin alfa therapy in CAPD patients by cross-over study.

• µµÁ¤È£(Do Jung-Ho) ±è´ëÁß(Kim Dae-Joong) ÃÖ¼Ò¿¬(Choi So-Yeon) µµ¿¬½Ç(Do Yeun-Sil) ÀåÀºÈñ(Jang Eun-Hee) ¹éÇöÁ¤(Beak Hyun-Jeong) ±èÁ¤ÀÎ(Kim Jung-In) ¿©È£¸í(Yeo Ho-Myoung) ÃÖ¼ºÃ¶(Choi Sung-Chul) ÀÌÁ¤Àº(Lee Jung-Eun) Çã¿ì¼º(Huh Woo-Sung) ±èÀ±±¸(Kim Yoon-Goo) ¿ÀÇÏ¿µ(Oh Ha-Young)

• ´ëÇѳ»°úÇÐȸÁö  2006³â 71±Ç 5È£ 527~534

• Åõ¼®À» ½ÃÀÛÇÏ´Â ¸»±â ½ÅºÎÀüÁõ ȯÀÚ¿¡¼­ Ç÷°ü ³»ÇǼ¼Æ÷ÀÇ ±â´ÉÀÌ»ó

• Usefulness of Peritoneal Dialysis (PD) in Patients with Refractory Heart Failure (RHF)

• À¯µ¿Àº(Yoo Dong-Eun) ±è½ÂÁØ(Kim Seung-Jun) ¹Ú¼±¿µ(Park Sun-Young) ¿ÀÇüÁß(Oh Hyung-Jung) ÀÌÇѼº(Lee Han-Sung) ÀÌÁ¤Àº(Lee Jung-Eun) ÃÖÈÆ¿µ(Choi Hoon-Young) ÇѽÂÇõ(Han Seung-Hyeok) ÇÑ´ë¼®(Han Dae-Suk) °­½Å¿í(Kang Shin-Wook)

• ´ëÇѽÅÀåÇÐȸÁö  2006³â 25±Ç 6È£ 991~998

• º¹¸·Åõ¼® ȯÀÚ¿¡¼­ µµ°ü °ü·Ã °¨¿° ¹× Àç¹ß¼º º¹¸·¿°¿¡¼­ µ¿½ÃÀû µµ°ü ±³Ã¼ÀÇ Ä¡·á È¿°ú

• The Effect of Simultaneous Catheter Removal and Replacement for Recurrent Peritonitis and Catheter-related Infections in Peritoneal Dialysis Patients

• À̱âÅ °ûÁøÈ£/ȲÀº¾Æ/Çѽ¿±/¹Ú¼º¹è/±èÇöö/±¸ÀÚÇö/±èÇüÅÂ/Á¶¿øÇö

• ´ëÇѽÅÀåÇÐȸÁö  2006³â 25±Ç 2È£ 205~211

• Pathogenesis and Treatment of Dyskalemia in Maintenance Hemodialysis and CAPD

• Kim HJ

• Electrolytes & Blood Pressure  2006³â 4±Ç 1È£ 47~52

• Åõ¼® ȯÀÚ¿¡¼­ Ç÷û ÀÌ¿ÂÈ­ ¸¶±×³×½· ÃøÁ¤

• Measurement of Serum Ionized Magnesium in Dialysis Patients

• ¼­Àå¿ø/Seo JW ±è¿µ¼ø/¼Õ±¤Ç¥/Çѽ¿ë/±è¼º±Õ/¿ÀÁöÀº/ÀÌ¿µ±â/±¸ÀÚ·æ/±èÇüÁ÷/³ëÁ¤¿ì/±è±ÙÈ£/Kim YS/Son KP/Han SY/Kim SG/Oh JE/Lee YK/Koo JR/Kim HJ/Noh JW/Kim GH

• ´ëÇѽÅÀåÇÐȸÁö  2005³â 24±Ç 6È£ 957~963

• Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼® ȯÀÚ¿¡¼­ °í¿ë·® (10,000 IU) Epoetin Alfa (¿¡½ºÆ÷Á¨^(¢ç))ÀÇ È¿°ú

• Effect of High Dose (10,000 IU) Epoetin Alfa (Espogen^(¢ç)) Therapy in CAPD Patients

• ¿©È£¸í/Yeo HM ±è´ëÁß/ÃÖ¼Ò¿¬/µµ¿¬½Ç/ÀåÀºÈñ/¹éÇöÁ¤/±è¹Î¿Á/±èÇöÁø/±èÁ¤¾Æ/Çã¿ì¼º/±èÀ±±¸/¿ÀÇÏ¿µ/Kim DJ/Choi SY/Do YS/Jang EH/Baek HJ/Kim MO/Kim HJ/Kim JA/Huh WS/Kim YG/Oh HY

• ´ëÇѽÅÀåÇÐȸÁö  2005³â 24±Ç 3È£ 441~447

• ±¹³» º¹¸·Åõ¼® ȯÀÚ¿¡¼­ ¹ß»ýÇÑ ±×¶÷¾ç¼º º¹¸·¿°ÀÇ °æÇèÀû ÃÊÄ¡·á Ç×»ýÁ¦ ¼±Åÿ¡¼­ ISPD °¡À̵å¶óÀÎÀÇ Å¸´ç¼º ºÐ¼®

• Empiric Therapy with Cefazolin and Ceftazidime (or Aminoglycoside) is Effective as the Initial Choice for the Treatment of Peritoneal Dialysis Related Peritonitis

• ¿À±¹È¯/Oh KH ±è¼º±Õ/±èÀç¼®/Á¤¿ì°æ/±è¼öÁø/½Å¿¬Èñ/±èÁÖ¿ø/Áֱǿí/±è¿¬¼ö/¾È±Ô¸®/¿ÀÁöÀº/Kim SG/Kim JS/Jung WK/Kim SJ/Shin YH/Kim JW/Joo KW/Kim YS/Ahn CR/Oh JE

• ´ëÇѽÅÀåÇÐȸÁö  2005³â 24±Ç 2È£ 204~214

• °È±â¿îµ¿ÀÌ º¹¸·Åõ¼® ȯÀÚÀÇ °Ç°­¿¡ ¹ÌÄ¡´Â È¿°ú

• Effects of Walking Exercise Program for Health Status in Patients on Continuous Ambulatory Peritoneal Dialysis

• À̼÷Á¤/Lee SJ ±èÇüÁ¾/À¯Áö¼ö/ÇÑÁö¿ø/¹Ú¾ç¼÷/Á¤¹®¿µ/½ÅÀº¾Æ/°­ÀÌÈ­/½Å¼®±Õ/Kim HJ/Yoo JS/Han JW/Park YS/Jung MY/Shin EA/Kang EW/Shin SK

• ´ëÇѽÅÀåÇÐȸÁö  2005³â 24±Ç 1È£ 126~136

• The Evolution of Lupus Activity among Patients with End-Stage Renal Disease Secondary to Lupus Nephritis

• Goo, Young Suck Park, Hyeong Cheon/Choi, Hoon Young/Kim, Beom Seok/Park, Yong Beom/Lee, Soo-Kon/Kang, Shin Wook

• Yonsei Medical Journal  2004³â 45±Ç 2È£ 199~206

• ¸»±â½ÅºÎÀü ȯÀÚ¿¡¼­ Åõ¼®¿¡ µû¸¥ Ç÷°ü °æÁ÷µµÀÇ º¯È­

• The Change of Arterial Stiffness According to Dialysis in Patients with End-Stage Renal Disease

• ÀÌ¿µ¼ö/Lee YS ±è±â½Ä/Çö´ë¿ì/ÇѼº¿í/Çã½ÂÈ£/±èÀ±³â/±è±Ç¹è/±Ç»ó¹Î/°­¹ÌÁ¤/Çѽ¿±/¹Ú¼º¹è/±èÇöö/Kim KS/Hyun DW/Han SW/Hur SH/Kim YN/Kim KB/Kwon SM/Kang MJ/Han SY/Park SB/Kim HC

• Korean Circulation Journal  2004³â 34±Ç 9È£ 865~873

• ½ÅüȰµ¿ °­È­ÇÁ·Î±×·¥ÀÌ º¹¸·Åõ¼®È¯ÀÚÀÇ ¿îµ¿ÀÌÇà, ¿ì¿ï, ºÒ¾È¿¡ ¹ÌÄ¡´Â È¿°ú

• The Effects of a Physical Activity Reinforcement Program on Exercise Compliance, Depression, and Anxiety in Continuous Ambulatory Peritoneal Dialysis Patients

• À̼÷Á¤/Lee SJ À¯Áö¼ö/Yoo JS

• Journal of Korean Academy of Nursing  2004³â 34±Ç 3È£ 440~448

• º¹¸·Åõ¼® ȯÀÚ¿¡¼­ ³­Ä¡¼º µµ°ü Ãⱸ °¨¿°¿¡ ´ëÇÑ Catheter RevisionÀÇ Ä¡·á È¿°ú

• The Effect of Catheter Revision on Intractable Exit Site Infection in CAPD Patients

• ±èÅ¿ì/Kim TW µµÁØ¿µ/À̽ÂÇö/¹èµ¿¿î/Á¶±ÔÇâ/¹ÚÁ¾¿ø/À±°æ¿ì/Do JY/Lee SH/Bae DU/Jo KH/Park JW/Yoon KW

• ´ëÇѽÅÀåÇÐȸÁö  2004³â 23±Ç 5È£ 753~762

• Comparative Study of Renal Replacement Therapy in Korean Diabetic End-Stage Renal Disease Patients

• Choi, So Rae Lee, Sang Cheol/Kim, Beom Seok/Yoon, Soo Young/Park, Hyeong Cheon/Kang, Shin Wook/Choi, Kyu Hun

• Yonsei Medical Journal  2003³â 44±Ç 3È£ 454~462

• ÀüºÏÁö¿ª Ç÷¾×Åõ¼® ȯÀÚ¿Í Áö¼Ó¼º ¿Ü·¡ º¹¸· Åõ¼® ȯÀÚÀÇ ¿µ¾ç»óÅ ºñ±³

• Characteristics in Nutritional Status of Patients on Hemodialysis and Continuous Ambulatory Peritoneal Patients in Chonbuk Area

• ±è¼±Çü ±è¼÷¹è

• Çѱ¹¿µ¾çÇÐȸÁö  2003³â 36±Ç 4È£ 397~404

• Åõ¼® ¹Þ´Â ¸»±â ½ÅÁúȯ ȯÀÚÀÇ ¼ö¸éÀå¾Ö

• Sleep Disorders in Maintenance Dialysis Patients with End-Stage Renal Disease

• Á¶¿ë¿ø/Cho YW ÀÌÇü/ÀÌÁÖÈ­/Çѽ¿±/À̹̿µ/Lee H/Lee JH/Han SY/Lee MY

• ´ëÇѽŰæ°úÇÐȸÁö  2003³â 21±Ç 5È£ 492~497

• ¸»±â ½ÅºÎÀü ȯÀÚ¿¡¼­ ù 12°³¿ù°£ÀÇ Åõ¼® ÈÄ¿¡ ÀÚÀ²½Å°æ°ú ¸»ÃÊ½Å°æ ±â´ÉÀÇ º¯È­

• Change of Autonomic and Peripheral Nerve Function after the First Twelve Months of Dialysis in End-stage Renal Disease

• ÀÓÁ¤¹¬/Leem JM ±èÇý¿µ/±Ç¼ø±æ/¹Ú¿µ¼±/À¯ÀÏ¿µ/È«ÀǽÇ/¾öÀçÈ£/ÀÌÇöÈñ/À̰湫/KIm HY/Kwon SG/Park YS/You IY/Hong ES/Earm JH/Lee HH/Lee KM

• ´ëÇѽÅÀåÇÐȸÁö  2002³â 21±Ç 5È£ 807~814

• ¸¸¼º ½ÅºÎÀü ȯÀÚ¿¡¼­ÀÇ ¹«Áõ»óÀû ¼¼±Õ´¢

• Asymptomatic Bacteriuria in Patients with Chronic Renal Failure

• Á¤À¯¼®/Jung YS ¾È½ÂÀç/¼ºÁø/±ÇÀºÈñ/À̵¿¿ø/À̼öºÀ/°ûÀÓ¼ö/³ªÇÏ¿¬/An SJ/Kim SJ/Kwon EH/Lee DW/Lee SB/Kwak IS/Rha HY

• ´ëÇѽÅÀåÇÐȸÁö  2002³â 21±Ç 5È£ 761~766

• ¸»±â ½ÅºÎÀü ȯÀÚ¿¡¼­ Åõ¿© °æ·Î¿¡ µû¸¥ À¯ÀüÀÚ ÀçÁ¶ÇÕ ÀÎ Erythropoietin (Epokine^¢ç)ÀÇ È¿°ú¿Í ¾ÈÁ¤¼º¿¡ ´ëÇÑ ¿¬±¸ - Á¦ ¥³ »ó ¿¬±¸ -

• Comparative Prospective Study of Intravenously and Subcutaneously Administered Recombinant Human Erythropoietin(Epokine^¢ç) in Ene-Stage Renal Disease Patients : A Phase ¥³ Single Center Study

• °­½Å¿í/Shin Wook Kang ÃÖ±ÔÇå/Çϼº±Ô/ÀÌÈ£¿µ/ÇÑ´ë¼®/¼ÛÇö¿ë/À±Çâ¼÷/Kyu Hun Choi/Sung Kyu Ha/Ho Yung Lee/Dae Suk Han/Hyun Yong Song/Hyang Suk Yoon

• ´ëÇѽÅÀåÇÐȸÁö  2002³â 21±Ç 2È£ 190~198

• ¸»±â ½ÅºÎÀü ȯÀÚ¿¡¼­ Åõ¿© °æ·Î¿¡ µû¸¥ À¯ÀüÀÚ ÀçÁ¶ÇÕ ÀÎ ¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾(rHuEPO)ÀÇ È¿°ú - È¿°ú¿Í °æÁ¦Àû Ãø¸é -

• Route of Administration of rHuEPO to Patients with End Stage Renal Diseases - Efficacy and Economic Considerations -

• °­Á¾¸í/Chong Myung Kang

• ´ëÇѽÅÀåÇÐȸÁö  2002³â 21±Ç 2È£ 185~189

• Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼® ȯÀÚ¿¡¼­ Åõ¿© °æ·Î¿¡ µû¸¥ Ä®½ÃÆ®¸®¿Ã È¿°úÀÇ ÀüÇâÀûÀÎ ºñ±³ ¿¬±¸

• A Prospective Study of the Effect of Calcitriol Treatment according to Administration Route in CAPD Patients

• ÀÌÀÎÈñ/In Hee Lee °­½Å¿í/³ëÇöÁø/½Å¼®±Õ/±èÀº°æ/ÃÖ±ÔÇå/Çϼº±Ô/À¯Çü½Ä/ÀÌÈ£¿µ/ÇÑ´ë¼®/Shin Wook Kang/Hyun Jin Noh/Sug Kyun Shin/Eun Kyung Kim/Kyu Hun Choi/Sung Kyu Ha/Hyung Sik Yoo/Ho Yung Lee/Dae Suk Han

• ´ëÇѽÅÀåÇÐȸÁö  2002³â 21±Ç 1È£ 148~158

• ´ç´¢º´¼º ½ÅÁõ°ú ºñ´ç´¢º´¼º ½ÅÁõ¿¡ ÀÇÇÑ ¸»±â ½ÅºÎÀü ȯÀÚ¿¡¼­ CAPDÀÇ ÀÓ»óºñ±³

• Comparison of CAPD in Patients with Diabetic and Non-diabetic ESRD

• ¼ÒÁ¤Àº/Joung Eun Soh ±èÈñÁø/ÀÌÅ¿ø/ÀåÇöÇÏ/ÀÓõ±Ô/±è¸íÁ¦/Hyun Ha Jang/Hee Jin Kim/Tae Won Lee/Chnn Gyoo Run/Myung Jae Kim

• °æÈñÀÇÇР 2002³â 18±Ç 1È£ 22~28

• ¸¸¼º ½ÅºÎÀü ȯÀÚ¿¡¼­ °íÈ£¸ð½Ã½ºÆ¾Ç÷Áõ¿¡ °üÇÑ ¿¬±¸

• Hyperhomocysteinemia in Patients with Chronic Renal Failure

• ¹Úº´¼® ±èÁ¤±â À̱ջó Á¶¹Î¼® ¹Ú¹ÌÁ¤ ¸¶¼º±Ç °íÁ¤Èñ

• ´ëÇѽÅÀåÇÐȸÁö  2001³â 20±Ç 4È£ 663~674

• ¸¸¼º½ÅºÎÀü ȯÀÚ¿¡¼­ Àå±â°£ Åõ¼®¿ä¹ý ÀüÈÄÀÇ Insulin-like Growth Factor ¹× Insulin-like Growth Factor Binding Proteins ÀÇ º¯È­

• The Changes of Growth Hormone, Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 Levels after Long-Term Dialysis Therapy

• ÀÌ°æÈÆ/Kyoung Hoon Lee ¹®Ä¡¿µ/±è¿ø/ÀÌ´ë¿­/¹Ú¼º±¤/°­¼º±Í/Chi Young Moon/Won Kim/Dae Yeol Lee/Sung Kwang Park/Sung Kyew Kang

• ´ëÇѽÅÀåÇÐȸÁö  2001³â 20±Ç 2È£ 180~186

• Break - in Period µ¿¾È ½ÃÇàÇÑ Ç÷¾× Åõ¼®ÀÌ Áö¼Ó¼º ¿Ü·¡ º¹¸· Åõ¼® ȯÀÚÀÇ ÀÜ¿© ½Å±â´É¿¡ ¹ÌÄ¡´Â ¿µÇâ

• The Effect of Hemodialysis During Break-in Period on Residual Renal Function in CAPD Patients

• ¹ÚÁø¾Æ/Ji Nah Park ±è´ëÁß/Á¤½ÃÁ¤/ÇÑÇõÁØ/Çã¿ì¼º/±èÀ±±¸/¿ÀÇÏ¿µ/Dae Joong Kim/Shi Jung Chung/Hyeok Jun Han/Woo Seong Huh/Yoon Goo Kim/Ha Young Oh

• ´ëÇѽÅÀåÇÐȸÁö  2001³â 20±Ç 1È£ 87~93

• º¹¸·Åõ¼®, Ç÷¾×Åõ¼® ¹× Á¤»ó ½Å ±â´É Áý´Ü°£ÀÇ ÀÎÁö±â´É ºñ±³ ¿¬±¸

• A Comparative Study in the Cognitive Functions of Peritoneal Dialysis, Hemodialysis and Normal Kidney Function Groups

• À̱â¼÷(Lee Gi-Sook) ÃÖ¼ÛÈñ(Choi Song-Hee)

• Korean Journal of Adult Nursing  2001³â 13±Ç 3È£ 451~462

• ¸¸¼º½ÅºÎÀü ȯÀÚ¿¡¼­ ½É±Ù troponin I¿Í T ¹× CK-MBÀÇ Áø´ÜÀû ÀÇÀÇ

• TnI, cTnT and CK-MB in patients with chronic renal failure

• 1À±Á¤ÀÌ/1Jung E Yun 1ÀÌÇüö/1ÀÌÁØ»ó/1¹Ú±Ô¿ë/1¹Ú´ë±Õ/1±¸ÀÚ·æ/1±èÇüÁ÷/1±è±ÙÈ£/1Àü³ë¿ø/1䵿¿Ï/1³ëÁ¤¿ì/2±èÇöÅÂ/2Á¶ÇöÂù/1Hyung Cheol Lee/1June Sang Lee/1Kyu Yong Park/1Dae Kyun Park/1Ja Ryong Goo/1Hyung Jik Kim/1Gheun Ho Kim/1Rho Won Chun/1Dong Wan Chae/1Jung Woo Noh/2Hyu

• ´ëÇѳ»°úÇÐȸÁö  2000³â 58±Ç 2È£ 204~212

• ¸»±â ½ÅºÎÀüÁõ ȯÀÚ¿¡¼­ Ç÷¾×Åõ¼®°ú Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼®ÀÇ ½ÃÀÛÀÌ Ç÷¾Ð¿¡ ¹ÌÄ¡´Â ¿µÇâ

• Effect of Initiation of Hemodialysis and Continuous Ambulatory Peritoneal Dialysis on Blood Pressure Control in Patients with End-Stage Renal Disease

• ¹Ú¿ì»ó/Woo Sang Park ¼ÛÁØÈ£/±è°æ¾Æ/ÀÌ°æÁÖ/À̽¿ì/±è¹®Àç/Joon Ho Song/Gyeong A Kim/Kyung Joo Lee/Seoung Woo Lee/Moon Jae Kim

• ´ëÇѽÅÀåÇÐȸÁö  2000³â 19±Ç 2È£ 320~326

• Åõ¼®Ä¡·á¸¦ ¹Þ´Â ¸¸¼º½ÅºÎÀü ȯÀÚÀÇ ºóÇ÷¿¡ ´ëÇÑ À¯ÀüÀÚ ÀçÁ¶ÇÕ ÀÎ ¿¡¸®Æ®·ÎÆ÷ÀÌ¿¡Æ¾(¿¡½ºÆ÷Á¨ )ÀÇ ÀÓ»óÈ¿°ú

• Clinical Trial Evaluating Efficacy and Safety of Recombinant Human Erythropoietin(Espogen ) in Dialysis Patients

• È£Áö¼÷/Gee Suk Ho Á¤¿ì°æ/¾È±Ô¸®/Çã¿ì¼º/È£ÇÏ¿µ/¹ÚÁ¤½Ä/Woo Kyung Chung/Cu Rie Ahn/Woo Sung Huh/Ha Young Oh/Jung Sik Park

• ´ëÇѽÅÀåÇÐȸÁö  2000³â 19±Ç 2È£ 312~319

• ¸»±â ½ÅºÎÀü ȯÀÚ¿¡¼­ µ¿¸Æ°æÈ­ÁõÀÇ ÀÓ»óÀû ÁöÇ¥¿Í °íÇØ»óµµ B¸ðµå °æµ¿¸Æ ÃÊÀ½ÆÄ ¼Ò°ßÀÇ »ó°ü¼º

• Relationship between Clinical Factors of Atherosclerosis and Carotid Artery on High Resolution B-mode Ultrasonography in End-stage Renal Disease Patients

• ¼ÛÁØÈ£/Joon Ho Song ±è°æ¾Æ/¹Ú°æ¼ö/À̽¿ì/±è¹®Àç/ÀÌâ±Ù/Gyeong A Kim/Kyeong Soo Park/Seonug Woo Lee/Moon Jae Kim/Chang Keun Lee

• ´ëÇѽÅÀåÇÐȸÁö  2000³â 19±Ç 2È£ 285~295

• Åõ¼®È¯ÀÚ¿¡¼­ ¼öºÐ °ú´ÙÁõÀÇ ÀÓ»óÀû ÀÇÀÇ

• Fluid Overload in Dialysis Patients

• ¹Ú¹Î¼± ÀÌÀº¾Æ

• ´ëÇѽÅÀåÇÐȸÁö  2000³â 19±Ç 2È£ 183~189

• Comparison of acquired cystic kidney disease between hemodialysis and continuous ambulatory peritoneal dialysis

• Byung Kee Bang/Jung Hee Park Young Ok Kim/Joo Hyun Park/Byung Soo Kim/Sun Ae Yoon/Chul Woo Yang/Yong Soo Kim/Chang Hee Han/Bum Soo Kim/Byung Kee Bang

• The Korean Journal of Internal Medicine  2000³â 15±Ç 1È£ 51~55

• Ç÷¾×Åõ¼®(HD)°ú º¹¸·Åõ¼® (CAPD) ȯÀÚ¿¡¼­ ÀÓ»ó°æ°úÀÇ ºñ±³ °üÂû

• Clinical Observation of Continuous Ambulatory Peritoneal Dialysis(CAPD) and Hemodialysis(HD) patients

• ±èÁß°æ ±èâ¼®/À±´ëÇö/¹Ú¿ë±â/½Å¿ëÈÆ/°¨º¹±Ô/Ç㵿/ÀåÀ͵æ/±è¹Ì¼±

• ´ëÇѳ»°úÇÐȸÁö  1998³â 55±Ç 3È£ 366~374

• ¸¸¼º ½ÅºÎÀü ȯÀÚ¿Í ½ÅÀÌ½Ä È¯ÀÚ¿¡¼­ Ç÷Àå ÃÑ È£¸ð½Ã½ºÅ×Àΰú ¿±»êÀÇ ³óµµ

• Plasma total homocysteine and folate concentration in patients with chronic renal failure and renal transplant recipients

• ±è¹ü/Beom Kim ÇÏ°æ¿ø/ÀÌÀ±ÇÏ/±èÇý¿µ/Çã¿ì¼º/±è´ëÁß/±èÀ±±¸/¿ÀÇÏ¿µ/Kyoung-won Ha/Yoon-Ha Lee/Hye-Young Kim/Wooseong Huh/Dae Joong Kim/Yoon-Goo Kim/Ha-Young Oh

• ´ëÇѳ»°úÇÐȸÁö  1998³â 55±Ç 1È£ 90~95

• Hepatitis G Virus Infection in Hemodialysis and Continuous Ambulatory Peritoneal Dialysis Patients

• Hyun Jin Noh/Hyun Jin Noh Shin Wook Kang/Seung Hyuk Choi/Sug Kyun Shin/Be Jeung Seo/In Hee Lee/Kyu Hun Choi/Dae Suk Han/Hyon Suk Kim*/Ho Yung Lee

• Yonsei Medical Journal  1998³â 39±Ç 2È£ 116~121

• ¸¸¼º ½ÅºÎÀü ȯÀÚ¿¡¼­ÀÇ Ç÷ûÁöÁú°ú Áö´Ü¹éÁú

• Serum Lipids and Lipoproteins in Patients with Chronic Renal Failure

• Á¤ÅÃ±Õ ±èÇö¼ö/³ª¸íÀ±/Á¤±ÕÈ£/Á¤±Ç/À̼ºÃ¶/±è¼ö¿Ï/±è³²È£/ÃÖ±âö

• ´ëÇѽÅÀåÇÐȸÁö  1998³â 17±Ç 5È£ 735~745

• Comparison of Plasma Amino Acid Concentrations in End-stage Renal Disease Patients on Hemodialysis and Peritoneal Dialysis

• Sae Yong Hong/Dong Hee Kim Dong Ho Yang/Sae Yong Hong

• The Korean Journal of Internal Medicine  1998³â 13±Ç 1È£ 33~40

• Åõ¼®¿ä¹ýÀÌ °©»ó¼± ±â´É º¯È­¿¡ ¹ÌÄ¡´Â ¿µÇâ

• Effcts of Hemodialysis and Contiuous Ambulatory Peritoneal Dialysis on Thyroid Function in Chronic Renal Failure Renal Failure Seung

• ±è½Â±â/Sung Kee Kim ±èÀÀ¼®/±è¿ë¼·/ÀÌÁ¤È£/½Å¿µÅÂ/Eung Suk Kim/Yoong Sub Kim/Jeong Ho Lee/Young Tae Sin

• ´ëÇѽÅÀåÇÐȸÁö  1997³â 16±Ç 4È£ 688~694

• Ç÷¾×Åõ¼® ¹× º¹¸·Åõ¼® ȯÀÚ¿¡¼­ °íÄ®½·Ç÷ÁõÀÇ ºóµµ

• Incidence of Hypercalcemia in Dialysis Patients : HD vs. CAPD

• ±èÁ¤È£ ÀÌÇö¾Æ/Á¤¹Ì°æ/ÀÌÀº¿µ/Â÷¹Ì°æ/¼Û°æÀÏ/¹Ú¹Î¼±/Çѵ¿Ã¶/Ȳ½Â´ö

• ´ëÇѽÅÀåÇÐȸÁö  1997³â 16±Ç 1È£ 94~100

• Åõ¼® Ä¡·áÁßÀÎ ¸¸¼º ½ÅºÎÀü ¼Ò¾Æ¿¡¼­ÀÇ ÁöÁú ¹× ÁöÁú´Ü¹é ÀÌ»ó

• Lipoprotein and Lipid Abnormalities in Uremic Children with Maintenance Dialysis

• ±èÁ¤¼ö/Jung Sue Kim Á¤ÇØÀÏ/ÃÖ¿ë/°í±¤¿í/¼ÛÁ¤ÇÑ/±èÁø±Ô/¹ÚÇý¿ø/Jung Han Song/Hye Won Park/Hae Il Cheong/Jin Q Kim/Yong Choi/Kwang Wook Ko

• ´ëÇѼҾƽÅÀåÇÐȸÁö  1997³â 1±Ç 2È£ 109~116

• Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼®(CAPD)°ú Ç÷¾×Åõ¼®(HD)ÀÇ ¿¹ÈÄ¿¡ °üÇÑ ºñ±³ ºÐ¼®

• Comparisons of Patient and Technique Wurvivals in Continuous Ambulatory Peritoneal Dialysis(CAPD) and Hemodialysis(HD)

• ¹éÁ¤Èì °ûÁø¿µ

• ´ëÇÑ¿Ü°úÇÐȸÁö  1996³â 50±Ç 4È£ 553~560

• ³ëÀÎ Åõ¼®È¯ÀÚÀÇ ¿µ¾ç»óÅ Æò°¡

• Assessment of Nutritional Status in Elderly Dialysis Patients

• À忬 (Timothy P Fleming) ÇÏÇýÁ¤ ¹Ú¿Á¼ø

• Journal of Korean Academy of Nursing  1996³â 26±Ç 2È£ 304~319

• Ç÷¾×Åõ¼® ¹× Áö¼Ó¼º ¿Ü·¡ º¹¸· Åõ¼® ȯÀÚÀÇ Ç÷û Lipoprotein(a) ³óµµ

• Comparison of Sernm tipoprotein(a) Concentration between Patients on Continuous Ambulatory Peritoneal Dialysis and Patients on Hemodialysis

• ¼­Àå¿ø À¯Çý½Â Á¤¿µ¿Á À¯±³»ó ¹Ú±¤Àç ±è»ïÁ¤ ÀÌ»ó±¸

• ´ëÇѽÅÀåÇÐȸÁö  1996³â 15±Ç 4È£ 558~566

• ÀÎü°èÃø°ú Infrared Interactance¸¦ ÀÌ¿ëÇÑ Ç÷¾×Åõ¼® ȯÀÚ¿Í º¹¸·Åõ¼® ȯÀÚ¿¡¼­ÀÇ ¿µ¾ç»óÅ ºñ±³¿¡ ´ëÇÑ ¿¬±¸

• Nutritional Comparison between Hemodialysis and Continuous Ambulatory Peritoneal Dialysis: Single-center Experience in Korea -Assessment of Nutrition with Anthropometry and Infrared Interactance-

• ±Ç¹Ì°æ ÇÑÀå±Ô ±è¿©ÁÖ ¼ÛÁØÈ£

• ÀÎÇÏÀÇ´ëÇмúÁö  1995³â 2±Ç 1È£ 63~68

• Comparative study of hepatitis C virus antibody between hemodialysis and continuous ambulatory peritoneal dialysis patients

• Lee, Ho Yung Kang, Duk Hee/Park, Chan Shin/Kim, Ki Yong/Kang, Shin Wook/Kim, Heung Soo/Choi, Kyu HuNm

• Yonsei Medical Journal  1993³â 34±Ç 4È£ 371~380

• Ç÷¾×Åõ¼® ¹× Áö¼Ó¼º º¹¸·Åõ¼® ȯÀÚ¿¡¼­ Carumonam(AMA-1080)ÀÇ ¾Çµ¿ÇÐ º¯È­¿¡ °üÇÑ ¿¬±¸

• Effect of Hemodialysis and Continuous Ambulatory Peritoneal Dialysis on Pharmacokinetics of Carumonam

• ÀÓµ¿¼® ½Å»ó±¸/Á¶Á¾ÅÂ/ÇÑÁø¼®/±è¼º±Ç/ÀÌÁ¤»ó/ÀÌ°æÈÆ/ÀåÀÎÁø

• ´ëÇѽÅÀåÇÐȸÁö  1993³â 12±Ç 1È£ 27~35

• Studies on IL-2 production and T-cell colony forming unit in patients with chronic renal failure

• Ha SK Cho HS/Lee HY/Kim HS/Choi KH/Han DS/Lee BK/Kim JD

• The Korean Journal of Internal Medicine  1993³â 8±Ç 2È£ 86~92

• Ç÷¾×Åõ¼® ȯÀÚ¿Í Áö¼ÓÀû ¿Ü·¡º¹¸·Åõ¼® ȯÀÚ¿¡¼­ÀÇ ¼º°øÀûÀÎ ÀӽŠ¹× Ãâ»êÀÇ °¢ 1¿¹

• Two Cases of Succssful Pregnancy Outcome with Hemodialysis and Continuous Ambulatory Peritoneal Dialysis Patient

• ¼Õ¼º¿í À̵¿¿¬/¾È¼÷¿µ/Á¤Àιè/Â÷µ¿¼ö/±è´ëÇö/Ãֽ¿í

• ´ëÇÑÁÖ»êÀÇÇÐȸÀâÁö  1993³â 4±Ç 3È£ 408~414

• ¸¸¼ºÇ÷¾× Åõ¼®È¯ÀÚ¿¡ ´ëÇÑ ¿ä·Î°¨¿°

• Urinary Tract Infection in Chronic Dialysis Patients

• À±°ßÀÏ(Yoon Kyun-Ill)

• ÀÌÈ­ÀÇ´ëÁö  1989³â 12±Ç 2È£ 99~104

• Studies on Lymphocyte Subpopulations and Cell-mediated lmmunity in Patients with Chronic Renal Failure

• Park, Kiil Ha, Sung Kyu/Han, Dae Suk

• Yonsei Medical Journal  1988³â 29±Ç 2È£ 109~116

• ¸¸¼º½ÅºÎÀüÁõ ȯÀÚ¿¡¼­ Ç÷Àå ¾Ë·ç¹Ì´½ ÃøÁ¤¿¡ °üÇÑ ¿¬±¸

• Plasma Aluminum Level in Chronic Renal Failure

• Á¶°áÀÚ ¹Ú¿ë°Ç ÀÌ¿ø±Ô ¾çÇöÁ¾ À¯°è¼±

• ´ëÇѽÅÀåÇÐȸÁö  1988³â 7±Ç 1È£ 68~74

• Çѱ¹ Á¤»óÀΰú ½ÅºÎÀüÁõȯÀÚ¿¡ ÀÖ¾î Ç÷¾× ¹× Á¶Á÷³»ÀÇ ±Ý¼Ó¿ø¼Òµé°ú ºÎ°©»ó¼± Ȧ¸óÀÇ »óÈ£°ü°è¿¡ °üÇÑ ¿¬±¸

• Plasma and Red Blood Cell Trace Elements in the Uremic and Dialysis Patients

• ÇÑ´ë¼® ÃÖ±ÔÇå ÀÌÈ£¿µ ÁÖÇö¿µ Çϼº±Ô Á¤¿ë ÀåÀ翬

• ´ëÇѽÅÀåÇÐȸÁö  1986³â 5±Ç 1È£ 53~60

• ¸»±â ½ÅºÎÀüÁõȯÀÚ¿¡¼­ Ç÷¾×Åõ¼®°ú CAPD¿ÍÀÇ ºñ±³ ¿¬±¸

• Comparison of Contnuous Ambulatory Peritoneal Dialysis and Hemodialysis

• ÃÖ±¤¼ö ÇѺ´ÈÆ/¹Úº´±Ô/·ùÀçÈ­/¹Ú¿äÇÑ/¹ÚÁø¼®/ÀÌÀç¿ì/À̽÷¡

• ´ëÇѳ»°úÇÐȸÁö  1985³â 29±Ç 6È£ 755~762